Long-term real-world evidence of SB5 (adalimumab biosimilar) treatment in patients with moderate-to-severe psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)

• Main Authors: Giampiero Girolomoni (Author), Steven R. Feldman (Author), Alexander Egeberg (Author), Luis Puig (Author), Jinah Jung (Author), Hojung Jung (Author), Younju Lee (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background SB5 (adalimumab-bwwd) is an adalimumab biosimilar targeting tumor necrosis factor (TNF) for the treatment of chronic inflammatory diseases, including moderate-to-severe chronic plaque psoriasis.Objectives To assess the four-year persistence associated with the effectiveness and safety of...